DK2833909T3 - Pcv/mycoplasma hyopneumoniae/prrs-kombinationsvaccine - Google Patents

Pcv/mycoplasma hyopneumoniae/prrs-kombinationsvaccine Download PDF

Info

Publication number
DK2833909T3
DK2833909T3 DK13717118.7T DK13717118T DK2833909T3 DK 2833909 T3 DK2833909 T3 DK 2833909T3 DK 13717118 T DK13717118 T DK 13717118T DK 2833909 T3 DK2833909 T3 DK 2833909T3
Authority
DK
Denmark
Prior art keywords
hyo
pcv2
antigen
lys
composition
Prior art date
Application number
DK13717118.7T
Other languages
English (en)
Inventor
Gregory P Nitzel
Jeffrey E Galvin
John Keith Garrett
James R Ii Kulawik
Tracy L Ricker
Megan Marie Smutzer
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48140160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2833909(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Application granted granted Critical
Publication of DK2833909T3 publication Critical patent/DK2833909T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (16)

1. Trivalent immunogen sammensætning omfattende supernatanten afen Mycoplasma hyopneumoniae (M.hyo)-kultur; et porcint circovirus type 2 (PCV2) antigen; og et porcin reproduktions- og respirationssygdom (PRRS)-virusanti-gen, hvor supernatanten af M.hyo-kulturen er blevet separeret fra uopløseligt cellulært materiale ved centrifugering, filtrering eller udfældning og er fri for både (i) IgG og (ii) immunkomplekser bestående af antigen, der er bundet til immunglobulin.
2. Sammensætning ifølge krav 1, hvor supernatanten af M.hyo-kulturen er blevet behandlet med protein-A eller protein-G, før den blev tilsat til den immunogene sammensætning.
3. Sammensætning ifølge krav 1 eller 2, hvor PRRS-virusantigenet er et genmodificeret levende virus.
4. Sammensætning ifølge et hvilket som helst af kravene 1 til 3, hvor PCV2-antigenet er i form af et kimært type 1-type 2-circovirus, hvilket kimære virus omfatter et inaktiveret rekombinant porcint circovirus type 1, der eksprimerer det porcine circovirus type 2-ORF2-protein.
5. Sammensætning ifølge et hvilket som helst af kravene 1 til 4, hvor PCV2-antigenet er i form af et rekombinant ORF2-protein.
6. Sammensætning ifølge krav 5, hvor det rekombinante ORF2-protein ekspri-meres fra en baculovirusvektor.
7. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, hvor sammensætningen yderligere omfatter en adjuvans.
8. Sammensætning ifølge krav 7, hvor adjuvansen er udvalgt fra gruppen bestående af en olie-i-vand-adjuvans, en polymer-og-vand-adjuvans, en vand-i-olie-adjuvans, en aluminiumhydroxid-adjuvans, en vitamin E-adjuvans og kombinationer deraf.
9. Sammensætning ifølge et hvilket som helst af kravene 1 til 8 til anvendelse ved immunisering afen gris imod M.hyo, PCV2 og PRRS-virus, som omfatter indgivelse af sammensætningen ifølge krav 1 til 8 til grisen.
10. Sammensætning til anvendelse ifølge krav 9, hvor sammensætningen indgives i en enkelt dosis.
11. Sammensætning til anvendelse ifølge krav 9 eller 10, hvor sammensætningen indgives til grise, som har maternelt afledte antistoffer mod mindst en af M.hyo, PCV2 og PRRS-virus.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 9 til 11, hvor sammensætningen indgives til grise, når de er er 3 uger gamle eller ældre.
13. Vaccinesammensætning omfattende en immunogen sammensætning ifølge et hvilket som helst af kravene 1 til 8, hvor sammensætningen yderligere omfatter en farmaceutisk acceptabel bærer.
14. Vaccinesammensætning ifølge krav 13 til anvendelse til beskyttelse af grise imod enzootisk pneumoni, PMWS (Post-weaning Multisystemic Wasting Syndrome) og porcin reproduktions- og respirationssygdom.
15. Kit omfattende en immunogen sammensætning eller vaccinesammensætning ifølge et hvilket som helst af kravene 1 til 14, hvor en første flaske omfatter både et PCV2-antigen og supernatanten af en Mycoplasma hyopneumoniae (M.hyo)-kultur, hvor supernatanten er fri for både (i) IgG og (ii) antigen/im-munglobulin-immunkomplekser, og en anden flaske omfatter PRRS-virusanti-gen; og eventuelt yderligere indbefattende en instruktionsmanual med anvisninger til kombinering af indholdet af den første flaske med indholdet af den anden flaske og til indgivelse af det kombinerede indhold af den første og anden flaske til en gris.
16. Fremgangsmåde til fremstilling af en immunogen sammensætning ifølge et hvilket som helst af kravene 1 til 14, hvilken fremgangsmåde omfatter: i) at dyrke M.hyo i et egnet medium overtidsrum på fra 18-144 timer; ii) efterfølgende at inaktivere M.hyo-kulturen; iii) at høste den inaktiverede kulturfluid, hvor den inaktiverede kulturfluid omfatter både en opløselig væskefraktion og uopløseligt cellulært materiale; iv) at separere den opløselige væskefraktion fra det uopløselige cellulære materiale ved filtrering, centrifugering eller udfældning; v) at fjerne både IgG og antigen/immunglobulin-immunkomplekserfra den fraseparerede væskefraktion til dannelse af M. hyo-kultur-supernatanten, der er fri for både (i) IgG og (ii) immunkomplekser bestående af antigen, der er bundet til immunglobulin; og vi) efterfølgende at kombinere supernatanten med et PCV2-antigen og PRRS-virusantigen.
DK13717118.7T 2012-04-04 2013-04-03 Pcv/mycoplasma hyopneumoniae/prrs-kombinationsvaccine DK2833909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620189P 2012-04-04 2012-04-04
PCT/US2013/035091 WO2013152086A1 (en) 2012-04-04 2013-04-03 Pcv/mycoplasma hyopneumoniae/prrs combination vaccine

Publications (1)

Publication Number Publication Date
DK2833909T3 true DK2833909T3 (da) 2019-04-01

Family

ID=48140160

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13717118.7T DK2833909T3 (da) 2012-04-04 2013-04-03 Pcv/mycoplasma hyopneumoniae/prrs-kombinationsvaccine

Country Status (33)

Country Link
US (2) US9125886B2 (da)
EP (2) EP3508217A1 (da)
JP (1) JP6271504B2 (da)
KR (1) KR101808903B1 (da)
AR (1) AR090614A1 (da)
AU (1) AU2013243540C1 (da)
BR (1) BR112014024775B1 (da)
CA (1) CA2869601C (da)
CL (1) CL2014002676A1 (da)
CO (1) CO7160027A2 (da)
CR (1) CR20140438A (da)
CY (1) CY1121578T1 (da)
DK (1) DK2833909T3 (da)
ES (1) ES2719483T3 (da)
GT (1) GT201400212A (da)
HK (1) HK1207283A1 (da)
HR (2) HRP20140956A2 (da)
HU (1) HUE042405T2 (da)
LT (1) LT2833909T (da)
MX (2) MX354773B (da)
MY (1) MY168549A (da)
NI (1) NI201400118A (da)
PH (1) PH12014502252A1 (da)
PL (1) PL2833909T3 (da)
PT (1) PT2833909T (da)
RS (1) RS58480B1 (da)
RU (1) RU2644256C2 (da)
SI (1) SI2833909T1 (da)
TR (1) TR201905176T4 (da)
TW (1) TWI504406B (da)
UA (1) UA114504C2 (da)
WO (1) WO2013152086A1 (da)
ZA (1) ZA201407133B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2027873T3 (da) 2001-07-02 2015-11-09 Zoetis Services Llc Enkeltdosisvaccination med mycoplasma hyopneumoniae
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CN104981252B (zh) 2012-12-28 2019-06-18 勃林格殷格翰动物保健有限公司 包含支原体抗原的免疫原性组合物
BR112015012711B1 (pt) 2012-12-28 2022-08-16 Boehringer Ingelheim Vetmedica Gmbh Método para preparar uma composição imunogênica para o tratamento e/ou a profilaxia de infecções por mycoplasma
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
US9951109B2 (en) * 2013-11-21 2018-04-24 Agricultural Technology Research Institute Composition for preventing Mycoplasma spp. infection
BR112016012435A8 (pt) 2013-12-03 2018-01-30 Intervet Int Bv vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
MX371126B (es) * 2013-12-03 2020-01-17 Intervet Int Bv Vacuna para cerdos contra el sindrome reproductivo y respiratorio porcino y lawsonia intracellularis.
CN104056265B (zh) * 2014-07-11 2016-04-27 江苏南农高科技股份有限公司 猪圆环病毒2型、猪繁殖与呼吸综合征二联疫苗及其制备方法
BR112017004703A2 (pt) * 2014-09-12 2017-12-05 Intervet Int Bv ?vacina e método para proteção de progênie de uma porca contra infeccção por um vírus de diarreia endêmica suína?
US10143738B2 (en) 2014-09-12 2018-12-04 Intervet Inc. Vaccine for use in protecting a pig against porcine epidemic diarrhea virus
EP3229832A1 (en) * 2014-12-11 2017-10-18 Intervet International B.V. Process for ready-to-use pcv2/m.hyo combination vaccine
AU2016380864B2 (en) * 2015-12-28 2019-10-31 Boehringer Ingelheim Animal Health USA Inc. M hyo multivalent vaccine and uses thereof
WO2017162741A1 (en) * 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection
JP7558638B2 (ja) 2016-03-23 2024-10-01 インターベット インターナショナル ベー． フェー． Ｐｃｖ２およびｐｒｒｓウイルス感染に対する皮内適用のためのワクチン
WO2018027526A1 (zh) * 2016-08-09 2018-02-15 财团法人农业科技研究院 防治猪鼻霉浆菌感染的组合物及生产该组合物的方法
KR102602018B1 (ko) * 2016-12-14 2023-11-15 조에티스 서비시즈 엘엘씨 젖떼기 전, 유럽의 돼지 생식기 및 호흡기 증후군 (prrs) 균주 바이러스에 대한 효과적인 백신접종
DK3558351T3 (da) * 2016-12-23 2022-03-21 Intervet Int Bv Kombinationsvaccine til svin
US11311614B2 (en) 2017-04-13 2022-04-26 Intervet Inc. Vaccines containing swine pathogens for associated non-mixed use
CN109280642B (zh) * 2017-07-21 2022-07-22 浙江海隆生物科技有限公司 CHO细胞株及其制备方法和使用该CHO细胞株制备猪圆环病毒2型Cap蛋白及其应用
US11744883B2 (en) 2017-12-22 2023-09-05 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
US11957746B2 (en) 2018-03-26 2024-04-16 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
CA1267087A (en) 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ZA881694B (en) 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
IE63692B1 (en) 1987-11-03 1995-05-31 Syntex Inc Vaccine adjuvant
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
WO1991018627A1 (en) 1990-05-29 1991-12-12 Smithkline Beecham Corporation Swine pneumonia vaccine and method for the preparation thereof
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
CA2290906C (en) 1991-06-06 2003-04-01 Stichting Centraal Diergeneeskundig Instituut Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
US5269315A (en) 1991-08-16 1993-12-14 The Regents Of The University Of California Determining the nature of brain lesions by electroencephalography
DE69214657T4 (de) 1991-08-26 2003-07-17 Boehringer Ingelheim Vetmed Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas)
CA2121241C (en) 1991-10-14 2007-12-04 Nicolaas Visser Porcine reproductive respiratory syndrome vaccine and diagnostic
ES2194841T3 (es) 1991-11-15 2003-12-01 Pfizer Procedimiento de produccion de vacunas bacterianas gram negativas.
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
ZA953703B (en) 1994-05-10 1996-01-10 American Home Prod Modified live BRSV vaccine
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0948625B1 (en) 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
KR20010032493A (ko) 1997-11-26 2001-04-25 아이오와 스테이트 유니버시티 리서치 파운데이션, 인코퍼레이티드 재조합 미코플라스마 히오뉴모니아(Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ) 백신
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
NZ513289A (en) 1998-12-22 2003-04-29 Pfizer Prod Inc Infectious cDNA clone of north american procine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
DK2027873T3 (da) 2001-07-02 2015-11-09 Zoetis Services Llc Enkeltdosisvaccination med mycoplasma hyopneumoniae
BR0211049A (pt) * 2001-07-02 2004-07-20 Pfizer Prod Inc Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
PT1546357E (pt) 2002-06-28 2013-09-10 Univ Iowa State Res Found Inc Polipéptidos imunogénicos de mycoplasma hyopneumoniae
NZ545289A (en) 2003-07-24 2008-05-30 Merial Ltd Vaccine formulations comprising an oil-in-water emulsion
ES2343201T3 (es) 2005-01-13 2010-07-26 Boehringer Ingelheim Vetmedica Gmbh Vacunas contra el srrp.
PL1926496T3 (pl) * 2005-09-09 2014-02-28 Intervet Int Bv Szczepionka przeciw PCV-2
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
CN102698263B (zh) 2005-12-29 2016-07-06 贝林格尔.英格海姆维特梅迪卡有限公司 多价pcv2免疫原性组合物和制备此类组合物的方法
DK2007419T3 (da) * 2006-04-10 2012-03-19 Intervet Int Bv Vaccine mod mycoplasma PRRSV
PL2007419T3 (pl) 2006-04-10 2012-09-28 Intervet Int Bv Szczepionka przeciwko mykoplazmie i PRRSV
MX2010005014A (es) * 2007-11-06 2010-06-30 Wyeth Llc Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
KR20130054466A (ko) 2008-10-16 2013-05-24 화이자 인코포레이티드 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
US20130064852A1 (en) 2010-05-11 2013-03-14 Intervet International B.V. Vaccine against mycoplasma, hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
BR112013004594B1 (pt) * 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
CA2866199A1 (en) 2012-03-07 2013-09-12 Ceva Sante Animale Novel veterinary vaccine
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine

Also Published As

Publication number Publication date
EP3508217A1 (en) 2019-07-10
TW201345548A (zh) 2013-11-16
LT2833909T (lt) 2019-04-10
AU2013243540A1 (en) 2014-10-09
CA2869601C (en) 2018-06-12
US9125886B2 (en) 2015-09-08
AR090614A1 (es) 2014-11-26
ZA201407133B (en) 2017-02-22
KR20150002748A (ko) 2015-01-07
RU2014140108A (ru) 2016-06-10
TR201905176T4 (tr) 2019-05-21
AU2013243540B2 (en) 2017-10-19
CN104271153A (zh) 2015-01-07
RS58480B1 (sr) 2019-04-30
HUE042405T2 (hu) 2019-06-28
NI201400118A (es) 2015-03-05
ES2719483T3 (es) 2019-07-10
MY168549A (en) 2018-11-12
HK1207283A1 (en) 2016-01-29
CL2014002676A1 (es) 2014-12-12
CA2869601A1 (en) 2013-10-10
AU2013243540C1 (en) 2018-03-01
BR112014024775B1 (pt) 2021-06-08
UA114504C2 (uk) 2017-06-26
GT201400212A (es) 2015-09-23
PH12014502252B1 (en) 2014-12-15
TWI504406B (zh) 2015-10-21
MX336502B (es) 2016-01-21
CR20140438A (es) 2014-11-12
MX2014012016A (es) 2014-11-10
CO7160027A2 (es) 2015-01-15
PH12014502252A1 (en) 2014-12-15
BR112014024775A2 (pt) 2017-07-11
JP2015512450A (ja) 2015-04-27
KR101808903B1 (ko) 2017-12-13
JP6271504B2 (ja) 2018-01-31
PT2833909T (pt) 2019-05-13
SI2833909T1 (sl) 2019-05-31
PL2833909T3 (pl) 2019-07-31
WO2013152086A1 (en) 2013-10-10
EP2833909B1 (en) 2019-02-06
RU2644256C2 (ru) 2018-02-08
EP2833909A1 (en) 2015-02-11
HRP20140956A2 (hr) 2015-04-24
MX354773B (es) 2018-03-20
CY1121578T1 (el) 2020-05-29
US9650601B2 (en) 2017-05-16
US20130266603A1 (en) 2013-10-10
US20150284678A1 (en) 2015-10-08
HRP20190466T1 (hr) 2019-05-03

Similar Documents

Publication Publication Date Title
US11141472B2 (en) Mycoplasma hyopneumoniae vaccine
DK2833909T3 (da) Pcv/mycoplasma hyopneumoniae/prrs-kombinationsvaccine
US11154609B2 (en) PCV/mycoplasma hyopneumoniae vaccine